The application of radionuclide antisense therapy for malignant tumours

Nuclear Medicine Communications

Volumn 22, Issue 5, 2001, Pages 469-472

  Zheng, Jianguo ^a   Tan, Tianzhi ^a  

^a FIRST AFFILIATED HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; LIPOSOME; RADIOISOTOPE;

CANCER THERAPY; CELL SURFACE; CYTOTOXICITY; DRUG MIXTURE; DRUG STABILITY; EDITORIAL; ENDOSOME; IONIZING RADIATION; ISOTOPE LABELING; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR BIOLOGY; ONCOGENE C MYC; ONCOGENE NEU; TRANSCRIPTION REGULATION;

DRUG DESIGN; DRUG STABILITY; HUMANS; NEOPLASMS; OLIGODEOXYRIBONUCLEOTIDES, ANTISENSE; ONCOGENES; RADIOPHARMACEUTICALS; RNA, MESSENGER;

EID: 0035023592     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/00006231-200105000-00001     Document Type: Editorial

References (5)

1. O’Brien SG, Kirkland MA, Goldman JM. European School of Oncology Task Force papers. Gene therapy: a future in cancer management? Antisense therapy for malignant disease. Eur J Cancer 1994; 30A: 1160-1164.
2. Hantowich DJ, Mardirossian G, Fogarasi M, et al. Comparative properties of a technetium-99m-labelled single-stranded natural DNA and a phosphorothioate derivative in vitro in mice. J Pharmacol Exper Theraps 1996; 276: 326-334.
3. Bennett CF. Antisense oligonucleotides: is the glass half full or half empty? Biochem Pharmacol 1998; 55: 9-19.
4. Citro G, Perrotti D, Cucco C, et al. Inhibition of leukemia cell proliferation by receptor-mediator uptake of c-myb antisense oligonucleotides. Proc Natl Acad Sci USA 1992; 82; 7031-7035.
5. Stein CA, Cheng YC. Antisense oligonucleotides as therpeutic agents - is the bullet really magical. Science 1993; 261: 1004-1012.